X4 Pharmaceuticals (XFOR) Short term Debt (2017 - 2023)

X4 Pharmaceuticals (XFOR) has reported Short term Debt for 6 consecutive years, with $764000.0 the latest figure, recorded in Q2 2023.

• For the quarter ending Q2 2023, Short term Debt fell 91.12% year-over-year to $764000.0; the trailing twelve-month figure through Jun 2023 stood at $764000.0 (down 91.12% YoY), and the FY2022 full-year result was $1.3 million, up 65.41% from the prior year.
• Short term Debt advanced to $764000.0 in Q2 2023 per XFOR's latest filing, from $554000.0 in the prior quarter.
• Across five years, Short term Debt topped out at $14.6 million in Q3 2022 and bottomed at $554000.0 in Q1 2023.
• Historically, Short term Debt has averaged $4.0 million across 4 years, with a median of $2.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Short term Debt surged 2009.81% in 2022, then tumbled 91.12% in 2023.
• Over 4 years, Short term Debt stood at $4.2 million in 2019, then plunged by 80.85% to $795000.0 in 2021, then surged by 65.41% to $1.3 million in 2022, then sank by 41.9% to $764000.0 in 2023.
• According to Business Quant data, Short term Debt over the past three periods registered $764000.0, $554000.0, and $1.3 million for Q2 2023, Q1 2023, and Q4 2022 respectively.